Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (151-160 of 755) with videos related to

Pageof 76
Sort By:
Clinical Pharmacokinetics|March 1, 1986
Clinical pharmacokinetics of oral and injectable gold compoundsK L Blocka, H E Paulus, D E Furst
Current Rheumatology Reports|March 9, 2016
Infection and Lupus: Which Causes Which?Sarah Doaty, Harsh Agrawal, Erin Bauer, et al.
The Journal of Rheumatology|February 1, 1987
Salicylate toxicity in elderly patients with rheumatoid arthritisR R Grigor, P W Spitz, D E Furst
Clinics in Dermatology|September 13, 2006
Systemic and localized sclerodermaLorinda Chung, Jan Lin, Daniel E Furst, et al.
The Journal of Rheumatology|May 1, 1992
Why everything (or nothing) seems to work in the treatment of sclerodermaJ R Seibold, D E Furst, P J Clements
Rheumatology (Oxford, England)|October 10, 2017
Points to consider for designing trials in systemic sclerosis patients with arthritic involvementPhilip Clements, Yannick Allanore, Daniel E Furst, et al.
Clinical Pharmacology and Therapeutics|September 1, 1979
Salicylate clearance, the resultant of protein binding and metabolismD E Furst, T N Tozer, K L Melmon
The Journal of Rheumatology|September 1, 1996
Results of "satisfaction with disease control" surveyD E Furst, K R Wilske, D E Stage
The Journal of Experimental Biology|March 15, 2002
Shell clamping behaviour in the limpet Cellana tramosericaGary K Ellem, John E Furst, Kenneth D Zimmerman
Seminars in Arthritis and Rheumatism|August 4, 2006
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionDaniel E Furst, Robert Wallis, Michael Broder, et al.
Pageof 76

Showing results (151-160 of 755) with videos related to

Sort By:
Pageof 76
Clinical Pharmacokinetics|March 1, 1986
Clinical pharmacokinetics of oral and injectable gold compoundsK L Blocka, H E Paulus, D E Furst
Current Rheumatology Reports|March 9, 2016
Infection and Lupus: Which Causes Which?Sarah Doaty, Harsh Agrawal, Erin Bauer, et al.
The Journal of Rheumatology|February 1, 1987
Salicylate toxicity in elderly patients with rheumatoid arthritisR R Grigor, P W Spitz, D E Furst
Clinics in Dermatology|September 13, 2006
Systemic and localized sclerodermaLorinda Chung, Jan Lin, Daniel E Furst, et al.
The Journal of Rheumatology|May 1, 1992
Why everything (or nothing) seems to work in the treatment of sclerodermaJ R Seibold, D E Furst, P J Clements
Rheumatology (Oxford, England)|October 10, 2017
Points to consider for designing trials in systemic sclerosis patients with arthritic involvementPhilip Clements, Yannick Allanore, Daniel E Furst, et al.
Clinical Pharmacology and Therapeutics|September 1, 1979
Salicylate clearance, the resultant of protein binding and metabolismD E Furst, T N Tozer, K L Melmon
The Journal of Rheumatology|September 1, 1996
Results of "satisfaction with disease control" surveyD E Furst, K R Wilske, D E Stage
The Journal of Experimental Biology|March 15, 2002
Shell clamping behaviour in the limpet Cellana tramosericaGary K Ellem, John E Furst, Kenneth D Zimmerman
Seminars in Arthritis and Rheumatism|August 4, 2006
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionDaniel E Furst, Robert Wallis, Michael Broder, et al.
Pageof 76